Patients with cystic fibrosis (CF) are repeatedly exposed to antibiotics, especially during the
pulmonary exacerbations of the disease. However, the available therapeutic strategies are …

Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic
fibrosis (CF) lung infections. In CF and other chronic diseases, AMR has a different profile …

The prevalence of antimicrobial resistance (AMR) is increasing and is a high priority
worldwide for interventions from antibiotic stewardship to new antibiotic development …

Chronic infection and inflammation are the hallmarks of cystic fibrosis lung disease. As cystic
fibrosis patients are living longer owing to more intense treatment, multidrug-resistant …

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …

Therapy for antibiotic-resistant bacterial infections in cystic fibrosis involves the use of new
laboratory methods (synergy testing or multiple-combination bactericidal testing) to optimize …

Median cystic fibrosis (CF) survival has increased dramatically over time due to several
factors, including greater availability and use of antimicrobial therapies. During the …

Chronic respiratory infection is the main cause of morbidity and mortality in cystic fibrosis
(CF) patients. One of the hallmarks of these infections, led by the opportunistic pathogen …

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …

Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to
advancements in antimicrobial treatments. New aerosolized antibiotic formulations have …